Oncolytics says pelareorep data show HPV-specific immune responses in anal cancer
Oncolytics Biotech reported translational data from a Phase 1/2 study in second-line or later squamous cell anal cancer patients, presented at the SITC 2026 Annual Meeting. The company said pelareorep combined with a checkpoint inhibitor more than doubled the objective response rate and increased median duration of response by 50% versus the current approved therapy in that population, though the immune data rest on small patient numbers.
Key points
- Seven of eight evaluable patients showed greater than two-fold increases in immune-activation biomarkers after one cycle of therapy
- Six of 14 patients evaluated for HPV-16 immune responses showed HPV-16 clonal expansion, and four of those had tumor shrinkage
- The company cited a potential $3 to 5 billion market for HPV-associated cancers, based on its internal estimates
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.